Modern aspects of diabetes mellitus type 2 treatment in cardiology practice (in the context of EASD/ADA consensus and Russian guidelines)
- Authors: Evdokimova A.G.1, Golikova A.A.1, Striuk R.I.1, Lobanova E.G.1
-
Affiliations:
- A.I.Yevdokimov Moscow State University of Medicine and Dentistry
- Issue: Vol 21, No 5 (2019)
- Pages: 69-77
- Section: Articles
- URL: https://journals.rcsi.science/2075-1753/article/view/96838
- DOI: https://doi.org/10.26442/20751753.2019.5.190449
- ID: 96838
Cite item
Full Text
Abstract
The article presents the importance of the problem of diagnostics and treatment of patients with diabetes mellitus (DM) type 2 in the light of steady increase of the prevalence of the disorder and its complications. Chronic hyperglycemia is a leading factor of cardiovascular disorders development associated with damage of eyes, kidneys, cardiac vessels, brain, and lower extremities arteries that results in disability and mortality of patients with DM type 2 and defines its social significance. The article provides definition of DM concept and classification, characterizes DM type 2 and other glycemic disorders diagnostic criteria. It is outlined that glycated hemoglobin (6.5% and more) is the diagnostic criterion for DM type 2. Special attention is given to glycemia self-control with the use of Contour™ Plus One glucometer, the distinguishing feature of which is the possibility of synchronization with mobile application Contour™ Diabetes. Therapeutic goals of DM type 2 treatment are defined according to ADA/EASD-2018 consensus (American Diabetes Association/ European Association for the Study of Diabetes) and Russian Association of Endocrinologists algorithms (2019). Recommendations for personalization of antihyperglycemic drugs choice in various clinical cases in consideration of rational drug combinations are given. Particular advantages of treatment using Russian guidelines are discussed.
Full Text
##article.viewOnOriginalSite##About the authors
Anna G. Evdokimova
A.I.Yevdokimov Moscow State University of Medicine and Dentistry
Email: aevdokimova@rambler.ru
д-р мед. наук, проф. каф. внутренних болезней Moscow, Russia
Anna A. Golikova
A.I.Yevdokimov Moscow State University of Medicine and DentistryD. Sci. (Med.), Prof. Moscow, Russia
Raisa I. Striuk
A.I.Yevdokimov Moscow State University of Medicine and DentistryD. Sci. (Med.), Prof. Moscow, Russia
Elena G. Lobanova
A.I.Yevdokimov Moscow State University of Medicine and DentistryD. Sci. (Med.), Prof. Moscow, Russia
References
- Глобальный доклад по диабету ВОЗ-2016. @@WHO 2016 Global Diabetes Report
- Алгоритмы специализированной медицинской помощи больным сахарным диабетом. Под ред. И.И.Дедова, М.В.Шестаковой, А.Ю.Майорова. Вып. 9. М.: Принт, 2019. DOI: 10.143.41/DM22131 @@Algorithms for specialized medical care for patients with diabetes. Pod red. I.I.Dedova, M.V.Shestakovoi, A.Iu.Maiorova. Vyp. 9. Moscow: Print, 2019. DOI: 10.143.41/DM22131
- Осложнение сахарного диабета: лечение и профилактика. Под ред. И.И.Дедова, М.В.Шестаковой М.: Медицинское информационное агентство, 2017. @@Complications of diabetes: treatment and prevention. Pod red. I.I.Dedova, M.V.Shestakovoi Moscow: Meditsinskoe informatsionnoe agentstvo, 2017
- Davies M.Y, Alessio D.A, Fradkin J et al. Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). EASD, ADA 2018. Diabetes Care 2018; 41: 2669-701. doi: 10.2337/dci18-0033
- Контур плюс. Руководство пользователя. Байер, 2013. @@Contour plus. User's manual. Baier, 2013
- Marso S.P, Daniels G.H, Brown-Fradsen V et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Eng J Med 2016; 275 (4): 311-22. doi: 10.1056/NEJMed16008827
- Wanner C, Lachin J.M, Inzucchi S.E et al. EMPA-REG OUTCOME Investigators. Circulation 2018; 137 (2): 119-29. doi: 10.1161/CIRCULATIONAHA.117.028268